CN103992405B - 抗-vegf抗体 - Google Patents

抗-vegf抗体 Download PDF

Info

Publication number
CN103992405B
CN103992405B CN201410106341.7A CN201410106341A CN103992405B CN 103992405 B CN103992405 B CN 103992405B CN 201410106341 A CN201410106341 A CN 201410106341A CN 103992405 B CN103992405 B CN 103992405B
Authority
CN
China
Prior art keywords
antibody
amino acid
district
cell
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410106341.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103992405A (zh
Inventor
柯耀煌
朱伟民
余国良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yikang Co
Original Assignee
Yikang Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yikang Co filed Critical Yikang Co
Publication of CN103992405A publication Critical patent/CN103992405A/zh
Application granted granted Critical
Publication of CN103992405B publication Critical patent/CN103992405B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201410106341.7A 2008-03-26 2008-10-08 抗-vegf抗体 Active CN103992405B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3971908P 2008-03-26 2008-03-26
US61/039,719 2008-03-26
CN200880128968.5A CN102065888B (zh) 2008-03-26 2008-10-08 抗-vegf抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880128968.5A Division CN102065888B (zh) 2008-03-26 2008-10-08 抗-vegf抗体

Publications (2)

Publication Number Publication Date
CN103992405A CN103992405A (zh) 2014-08-20
CN103992405B true CN103992405B (zh) 2016-08-17

Family

ID=41114205

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410106341.7A Active CN103992405B (zh) 2008-03-26 2008-10-08 抗-vegf抗体
CN200880128968.5A Active CN102065888B (zh) 2008-03-26 2008-10-08 抗-vegf抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200880128968.5A Active CN102065888B (zh) 2008-03-26 2008-10-08 抗-vegf抗体

Country Status (9)

Country Link
US (2) US7803371B2 (OSRAM)
EP (1) EP2259795B1 (OSRAM)
JP (2) JP5823858B2 (OSRAM)
KR (1) KR101581244B1 (OSRAM)
CN (2) CN103992405B (OSRAM)
AU (1) AU2008353479B2 (OSRAM)
BR (1) BRPI0822556B1 (OSRAM)
CA (3) CA2719400C (OSRAM)
WO (1) WO2009120178A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20241467T1 (hr) 2008-06-25 2025-01-03 Novartis Ag Stabilna i topljiva protutijela koja inhibiraju vegf
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
CN102686609A (zh) * 2009-10-23 2012-09-19 加文医学研究所 修饰的可变域分子及其生产和使用方法
JP6097702B2 (ja) * 2011-03-03 2017-03-15 アペクシジェン， インコーポレイテッド 抗ｉｌ−６受容体抗体およびその使用方法
CN103087192B (zh) * 2011-11-02 2015-02-04 埃派斯进有限公司 抗-kdr抗体和使用方法
CN103417965B (zh) * 2012-05-17 2018-04-13 江苏先声药业有限公司 一种含有抗vegf抗体的药物组合物
CN103417964A (zh) * 2012-05-17 2013-12-04 江苏先声药物研究有限公司 一种抗vegf抗体的用途
MY199344A (en) 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof
CN105263959A (zh) * 2013-12-31 2016-01-20 财团法人生物技术开发中心 抗vegf抗体及其用途
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
WO2016115521A1 (en) * 2015-01-16 2016-07-21 Alder Biopharmaceuticals, Inc. Anti-glycoprotein antibodies and uses thereof
MX2017015908A (es) * 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
WO2021046653A1 (en) * 2019-09-13 2021-03-18 Centre For Drug Research And Development Anti-oncolytic virus antigen antibodies and methods of using same
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4642805A4 (en) * 2022-12-29 2026-04-22 Ltz Therapeutics Inc Anti-cd79b antibodies and uses thereof
CN118344476B (zh) * 2024-05-16 2024-11-15 武汉爱博泰克生物科技有限公司 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299833A (zh) * 1999-12-30 2001-06-20 华西医科大学口腔医学研究所 抗人血管内皮生长因子单链抗体及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
EP1539947A4 (en) * 2002-08-15 2006-09-06 Epitomics Inc HUMANIZED RABBIT ANTIBODIES
US20050033031A1 (en) * 2003-08-07 2005-02-10 Couto Fernando Jose Rebelo Do Methods for humanizing rabbit monoclonal antibodies
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
HUE038432T2 (hu) * 2008-06-25 2018-10-29 Esbatech Alcon Biomed Res Unit Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299833A (zh) * 1999-12-30 2001-06-20 华西医科大学口腔医学研究所 抗人血管内皮生长因子单链抗体及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
利用重组人VEGF165制备单克隆抗体的研究;孙大军等;《白求恩医科大学学报》;20010930;第27卷(第05期);摘要、第2.4节 *
抗人VEGF165单链抗体的构建与表达;赵泽国等;《免疫学杂志》;20000225;第16卷(第02期);摘要 *

Also Published As

Publication number Publication date
US7803371B2 (en) 2010-09-28
AU2008353479B2 (en) 2014-02-20
US8088375B2 (en) 2012-01-03
EP2259795A4 (en) 2012-06-06
CA2981887A1 (en) 2009-10-01
WO2009120178A1 (en) 2009-10-01
JP5823858B2 (ja) 2015-11-25
CN102065888A (zh) 2011-05-18
CA2981887C (en) 2019-09-03
CN102065888B (zh) 2014-03-26
AU2008353479A1 (en) 2009-10-01
CN103992405A (zh) 2014-08-20
BRPI0822556B1 (pt) 2022-03-03
EP2259795A1 (en) 2010-12-15
HK1201280A1 (en) 2015-08-28
CA3053675A1 (en) 2009-10-01
CA2719400A1 (en) 2009-10-01
KR20100132983A (ko) 2010-12-20
JP2014205674A (ja) 2014-10-30
CA2719400C (en) 2017-11-14
BRPI0822556A2 (pt) 2020-08-18
US20110008367A1 (en) 2011-01-13
US20090246190A1 (en) 2009-10-01
JP2011517447A (ja) 2011-06-09
EP2259795B1 (en) 2016-04-06
KR101581244B1 (ko) 2015-12-31

Similar Documents

Publication Publication Date Title
CN102065888B (zh) 抗-vegf抗体
CN102448987B (zh) 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
CN111234020B (zh) 一种bcma结合蛋白及其制备方法和应用
CN107011434A (zh) 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
CN110357963A (zh) 抗人st2抗体及其用途
CN116284373A (zh) 非pH依赖性长效型抗血清白蛋白纳米抗体及其应用
CN116589564B (zh) 抗aav5抗体及快速aav5滴度测定elisa试剂盒
US20230279127A1 (en) Il12 receptor synthetic cytokines and methods of use
KR20250173509A (ko) 클라우딘18.2에 특이적으로 결합하는 항체, 및 이의 제조 방법 및 이의 응용
CN104045713B (zh) 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
CN119661721B (zh) 一种抗甘胆酸抗体及其应用
US20230272088A1 (en) Ifngr binding synthetic cytokines and methods of use
TWI698643B (zh) 用於檢測米田堡血型抗原的抗體及其片段、試劑盒及方法
CN120623352B (zh) 抗human IgG的抗体、其制备方法及用途
CN117043192B (zh) 针对IL-13Rα2的抗体及其应用
AU2014202474B2 (en) Anti-VEGF antibody
HK1201280B (en) Anti-vegf antibody
HK40031847A (en) A bcma binding protein and method for preparation and application thereof
HK40031847B (en) A bcma binding protein and method for preparation and application thereof
CN109709337A (zh) 人cd26的免疫组化检测试剂盒及其临床应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201280

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1201280

Country of ref document: HK